AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06774846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acetylsalicylic acid (100 mg) / 0.9% sodium chloride
Description: patients in the placebo group will receive 100 mg placebo acetylsalicylic acid orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
Study NCT06772116 — intervention group
Intervention type: PROCEDURE
Intervention: Focal Therapy
Description: Primary focal treatment (targeted or partial gland ablation) of PCa lesion(s) detected on mpMRI, where a PCa ISUP 2 or 3 has been identified (PCa ISUP 1 outside the treatment areas is acceptable, regardless of volume).~Focal treatment will be performed using one of the following energy-based techniques: high-intensity focused ultrasound (HIFU), cryotherapy (CRYO), brachytherapy (BT), irreversible electroporation (IRE), focal laser ablation (FLA), vascular-targeted photodynamic therapy (VTP), or radiofrequency ablation (RFA). The specific technique will depend on the rules, approvals, and regulations of the country where the treatment is performed.
Study NCT06774118 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study NCT05796986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular procedure of treatment of wide neck saccular cerebral aneurysm
Description: Endovascular different modalities for occlusion of wide neck saccular cerebral aneurysms include stent assisted coiling or balloon assisted coiling or flow diverter or 3D coiling
Study NCT06159075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
Study NCT05891067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SterkWerk
Description: Classroom-based intervention program
Study NCT05891067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Active control group
Study NCT06770621 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia test
Description: For these tests, multiple blood samples will be collected during insulin-induced hypoglycemia (stage 1 hypoglycemia is defined as a blood glucose level below 70 mg/dL, while stage 2 corresponds to values below 54 mg/dL). The tests will be conducted on patients who have fasted for at least 12 hours and will be supervised by a medical staff member trained to manage severe hypoglycemia.
Study NCT06770621 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-induced hypoglycemia test
Description: For these tests, multiple blood samples will be collected during insulin-induced hypoglycemia (stage 1 hypoglycemia is defined as a blood glucose level below 70 mg/dL, while stage 2 corresponds to values below 54 mg/dL). The tests will be conducted on patients who have fasted for at least 12 hours and will be supervised by a medical staff member trained to manage severe hypoglycemia.
Study NCT06770621 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucagon profile
Description: The subject must fast before the consultation and follow a specific diet the day before; after an initial blood draw (P1), the patient will have breakfast and take any required insulin, followed by two additional blood draws 1.5 hours after breakfast (P2) and 1.5 hours after P2 (P3)
Study NCT06770621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample once
Description: The exome of each patient will then be analyzed from the blood sample taken beforehand.
Study NCT06770621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation-questionnaire
Description: only the answer to a questionnaire
Study NCT06770764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODC-IL2
Description: ODC-IL2 as a single agent infused IV over 60 minutes on Days 1 and 15 of a 28 day cycle.
Study NCT06772090 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus and Bifidobacterium
Description: Each lot of Lactobacillus and Bifidobacterium and placebo capsules to be used in this study will undergo bioburden testing (tested as per USP \<61>) to ensure that each lot has:~* Not more than 2000 colony forming unit (CFU) of contaminating (other than the seven strains of bacteria used in the Lactobacillus and Bifidobacterium capsules) aerobic bacteria per gram or dose (whichever is greater);~* Not more than 200 CFU of yeasts and molds per gram or dose (whichever is greater); and~* No bile-tolerant Gram-negative bacteria, Escherichia coli, Salmonella species (in 10 gm), Pseudomonas aeruginosa, Staphylococcus aureus, and Clostridium species per gram or dose (whichever is greater; tested as per USP\<62>).
Study NCT06772090 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule manufactured in same facility as experimental capsule.
Study NCT06775028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iABC platform use
Description: The novel platform (iABC) that will be used in AFFIRMO will consist of an educational program, a healthy or functional diet/physical activity, guideline-adherent drug treatments, periodic (re)assessment.
Study NCT06774417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital nudge
Description: Digital help seeking advancement strategies over text and online.
Study NCT06774885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid 1 Mg Oral Tablet
Description: 1 mg oral folic acid tablet
Study NCT06774885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid 5 Mg Oral Tablet
Description: 5 mg oral folic acid tablet
Study NCT06154577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Assessment of tongue morphology and posterior airway space using ultrasonography (AmCAD-UO, CE mark NB1639)
Study NCT06296121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-264
Description: IV, 16 mg/kg
Study NCT06296121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darzalex
Description: IV, 16 mg/kg
Study NCT06484894 — intervention group
Intervention type: DEVICE
Intervention: Pentacam and IOL master
Description: Device used for measurement of central corneal thickness
Study NCT04839861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mightier Family Games
Description: Mightier Family Games includes five offline card games that can be played by two or more people. During card game play, one player wears the Mightier heart rate monitor, and can see a representation of their heart rate on a separate screen within the Mightier app. Each game includes elements that are tied to heart rate.
Study NCT04839861 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mightier online gameplay
Description: Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own.
Study NCT04839861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mightier online gameplay
Description: Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own.
Study NCT04931836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Three walking sessions/week for a total of 8 weeks (24 total sessions) - Walking sessions will either take place on new commercial treadmills in the Epidemiology Clinical Research Center or remotely at or around a participant's home. Regardless of the walking location, walking sessions will be 30 min in duration during intervention weeks 1 through 4 and a minimum of 45 min each during intervention weeks 5 through 8.
Study NCT06525077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT218
Description: Sodium oxybate for extended-release oral suspension
Study NCT06525077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo equivalent for oral suspension
Study NCT04922307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sparing Protocol
Description: Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass
Study NCT04922307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Blood Replacement
Description: Allogenic blood transfusion as determined intra-operatively
Study NCT06346379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Baduanjin has 8 movement forms, which are easy to learn without special equipment.These advantages make Baduanjin a suitable exercise for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully.During the exercise of Baduanjin, the knees are half bent and the body center of gravity is stable between the feet, which can effectively develop the strength and endurance of skeletal muscle groups, improving the physical fitness and Bone mineral density.
Study NCT05673148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Undergo SABR
Study NCT05673148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: undergo surgical resection
Study NCT05673148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: undergo microwave ablation
Study NCT05673148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive SOC chemotherapy
Study NCT05673148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Receive SOC chemotherapy
Study NCT05673148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05673148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05673148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05673148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05673148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT05673148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT06531499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA617
Description: \[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for up to 12 cycles.
Study NCT06531499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analogues
Description: Anatomical Therapeutic Chemical \[ATC\] code L02AE
Study NCT06531499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) antagonists
Description: Degarelix, Relugolix
Study NCT06487650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep intervention
Description: At the beginning of the intervention, participants will have an orientation and overview of the program. Then, participants will follow the curriculum of modules, and professional feedback to complete the intervention.
Study NCT06487650 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants in control group will follow standardized usual care and a perinatal health booklet
Study NCT06771934 — intervention group
Intervention type: BIOLOGICAL
Intervention: Allergen-specific immunotherapy(AIT)
Description: Allergen-Specific Immunotherapy(AIT) Protocol: using the house dust mite allergen preparation (Alutard, ALK Company, Denmark). The treatment course was divided into the initial treatment stage and the maintenance treatment stage. The initial treatment stage, also known as the dose accumulation stage, involved injecting the vaccine once a week and usually lasted for 15 weeks. For highly sensitive patients, treatment was carried out according to the dose guidelines for high sensitivity. The maximum dose in the initial treatment stage was the maintenance dose. After reaching the maintenance dose, the first maintenance injection was given 2 weeks later, the second maintenance injection was given 4 weeks later, and thereafter, a vaccine injection was carried out every 4 - 8 weeks.
Study NCT06771934 — intervention group
Intervention type: BIOLOGICAL
Intervention: omalizumab
Description: Omalizumab Treatment Protocol: The dosage and administration frequency (once every 2 weeks or once every 4 weeks) of omalizumab were determined based on the patients' pretreatment serum total IgE (kU/L), age, and body weight (kg). Each dosage ranged from 15 to 600 mg and was administered subcutaneously. If the dosage was ≤ 150 mg, it was injected subcutaneously at 1 site; otherwise, it was injected subcutaneously at 1 to 4 sites respectively. After the first 3 injections, patients were observed in the hospital for at least 2 hours, and after the 4th and subsequent injections, they were observed for at least 30 minutes. During the treatment period, the background medications for asthma control were adjusted according to the patient's condition.
Study NCT06770218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic girdle stability training and therapeutic tapping
Description: pelvic girdle stability training performed along with therapeutic taping in experimental group tapping involves applying strips one and two over the paraspinal region from l4 to t1 in a caudo cephalic directions. strips 3 and 4 along the lower portion of trapezius with a medially directed force from the acromion process to T12 obliquely. total session time 45 minutes to 60 minutes
Study NCT06770218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pelvic girdle stability training only
Description: participates engaged in pelvic girdle stability training focusing on exercises therapeutics taping was not be administrated during these stability exercises. excercise include pelvic brigde, one leg bridge, calm exercise for gluteus medius, leg lift 4 point kneelig arm lift
Study NCT06772870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-216P2
Description: DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.
Study NCT06772870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline solution will be used as placebo control.
Study NCT06021704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced home health aide training in dementia and dementia-related behaviors
Description: 8 hours (2 instructional days) of enhanced curriculum dementia-specific instruction for home health aides
Study NCT06023394 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laryngeal Mask Airway
Description: Laryngeal mask airway will be used as an airway device for Cohort A in the standard fashion.
Study NCT06023394 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endotracheal Tube Device
Description: Endotracheal tube airway will be used as an airway device for Cohort B in the standard fashion.
Study NCT06770712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The patients were asked to sit in front of a table at an appropriate height and rest their arms on the table. A mirror was placed between both arms. The mirror was positioned so that the reflection of the healthy extremity overlapped with the paralytic extremity. In this way, the movements of the healthy upper extremity were viewed through the mirror, creating a visual movement illusion for the hemiplegic upper extremity. During the mirror therapy, exercises including forearm supination-pronation, wrist flexion-extension, finger flexion-extension, finger counting, grasping and releasing a cup, grasping and releasing a ball, and writing with a pen were performed. First, 30 minutes of bilateral TENS therapy were applied, followed by 30 minutes of mirror therapy
Study NCT06770712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Received stimulation on the extensor muscles of the hand fingers of both the intact and paretic sides, with a frequency of 100 Hz, pulse width of 200 microseconds, and a biphasic symmetric pulse for 30 minutes. The current intensity was adjusted to a level that induced visible muscle contractions and was set to twice the sensory threshold. Self-adhesive electrodes, measuring 5x5 cm, were placed on the extensor surface of the forearm, 5 cm distal to the olecranon, parallel to the long axis of the muscle. Electrical stimulation was applied using the Cefar Rehab X2 device (DJO France SAS).
Study NCT06770712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Received stimulation on the extensor muscles of the hand fingers of both the intact and paretic sides, with a frequency of 100 Hz, pulse width of 200 microseconds, and a biphasic symmetric pulse for 30 minutes. The current intensity was adjusted to a level that induced visible muscle contractions and was set to twice the sensory threshold. Self-adhesive electrodes, measuring 5x5 cm, were placed on the extensor surface of the forearm, 5 cm distal to the olecranon, parallel to the long axis of the muscle. Electrical stimulation was applied using the Cefar Rehab X2 device (DJO France SAS).
Study NCT06252285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVt Vaccine
Description: Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
Study NCT06252285 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
Study NCT06276374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patients who are scheduled to undergo carotid artery stenting
Description: * Arm A : Single antiplatelet therapy (SAPT) with aspirin or clopidogrel~  - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)~* Arm B : Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)
Study NCT06276374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients who are scheduled to undergo carotid artery stenting
Description: * Arm A : Single antiplatelet therapy (SAPT) with aspirin or clopidogrel~  - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)~* Arm B : Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)
Study NCT06082804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APN and medical management
Description: Patients are followed by the advanced practice nurse and the hematologist.
Study NCT06082804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: Patients are followed by the hematologist only (standard of care).
Study NCT06082804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Description: EORTC-QLQ-C30 questionnaire
Study NCT06082804 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life assessment
Description: EORTC-QLQ-C30 questionnaire
Study NCT06082804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment compliance assessment
Description: GIRERD questionnaire
Study NCT06082804 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment compliance assessment
Description: GIRERD questionnaire
Study NCT04828954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization for 2-weeks postoperative
Description: Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks